LINC02151: A Protein Implicated in Many Diseases (G109729162)

Target Name: LINC02151

NCBI ID: G109729162

LINC02151

Other Name(s): TCONS_00019174 | Long intergenic non-protein coding RNA 2151 | long intergenic non-protein coding RNA 2151

LINC02151: A Protein Implicated in Many Diseases

LINC02151 (TCONS-00019174) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of cell proliferation and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of LINC02151 is to control the cell cycle. The cell cycle is the process by which cells grow, divide, and replicate their genetic material. LINC02151 is involved in the regulation of the G1/S transition, which is the stage of the cell cycle where the cell prepares for cell division.

Mutations in the LINC02151 gene have been implicated in a number of diseases, including cancer. For example, studies have shown that LINC02151 mutations are commonly found in various types of cancer, including breast, ovarian, and prostate cancer. In addition, LINC02151 has also been implicated in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Another function of LINC02151 is to regulate the immune system. LINC02151 has been shown to play a key role in the regulation of T cell development and function. T cells are a type of immune cell that play a critical role in protecting the body against infection and disease. LINC02151 mutations have been shown to impair the function of T cells, which could have implications for both cancer and neurodegenerative diseases.

In addition to its functions in regulating the cell cycle and immune system, LINC02151 has also been shown to play a role in the regulation of cell adhesion. Cell adhesion refers to the interaction between cells that results in the formation of tight junctions and adherens junctions, which are essential for maintaining tissue structure and function. LINC02151 mutations have been shown to affect the formation of these tight junctions and adherens junctions, which could have implications for various diseases, including cancer.

Finally, LINC02151 has also been shown to play a role in the regulation of cellular signaling pathways. LINC02151 has been shown to be involved in a number of signaling pathways, including the PI3K/Akt signaling pathway, the TGF-β signaling pathway, and the NF-kappa-B signaling pathway. These signaling pathways are important for the regulation of various cellular processes, including cell growth, differentiation, and inflammation.

In conclusion, LINC02151 is a protein that is involved in a number of important cellular processes in the body. Its functions in regulating the cell cycle, immune system, and cell adhesion, as well as its role in the regulation of cellular signaling pathways, make it an attractive target for research into a variety of diseases. Further research is needed to fully understand the role of LINC02151 in these processes and to develop effective therapies for the treatment of these diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 2151

The "LINC02151 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02151 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets